3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
5
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colonic Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
lenvatinib
9
vandetanib
5
pembrolizumab
4
Sorafenib
4
selpercatinib
3
Thyrotropin Alfa
3
trametinib
2
fosbretabulin
2
combretastatin
2
cabozantinib
2
belinostat
2
Paclitaxel
2
Gemcitabine
2
Fluorouracil
2
Cetuximab
2
Carboplatin
2
Axitinib
2
130-nm albumin-bound paclitaxel
2
ulixertinib
1
trastuzumab deruxtecan
1
tipifarnib
1
surufatinib
1
repotrectinib
1
pralsetinib
1
naporafenib
1
motesanib diphosphate
1
methyl N-acetylsibirosaminide
1
larotrectinib
1
irofulven
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thyroid Neoplasms
×
naporafenib
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled